Response-based Treatment of High-risk Neuroblastoma
Newly Diagnosed High Risk Neuroblastoma
About this trial
This is an interventional treatment trial for Newly Diagnosed High Risk Neuroblastoma focused on measuring Neuroblastoma, High risk, Tandem high dose chemotherapy
Eligibility Criteria
Inclusion Criteria:
- Patients with newly diagnosed high risk neuroblastoma
- Patients with informed consent
Exclusion Criteria:
- Patients with progressive disease or relapse
- Patients who underwent high dose chemotherapy before
- Patients with organ dysfunction as follows (creatinine elevation > 3 x upper limit of normal, Total bilirubin > 3 x upper limit of normal, aspartate transaminase/alanine transaminase > 5 x upper limit of normal), ejection fraction <40%
- Pregnant or nursing women
Sites / Locations
- Samsung Medical CenterRecruiting
Arms of the Study
Arm 1
Experimental
High risk neuroblastoma
Nine cycles of induction chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen Upfront surgery or surgery after 6 cycles of chemotherapy Peripheral stem cell mobilization after 7 cycles of chemotherapy Tandem high dose chemotherapy with autologous stem cell transplantation (Tandem HDCT/auto-SCT) Dose of chemotherapeutic agents of 1st HDCT is tailored according to the residual positron emission tomography (PET)/Metaiodobenzylguanidine (MIBG) uptake before 1st HDCT Dose of MIBG of 2nd HDCT is tailored according to the residual PET/MIBG uptake before 2nd HDCT Radiotherapy after tandem HDCT Immunotherapy and differentiation therapy with Interleukin-2/isotretinoin